AlphAIalphai — Financial news for AI agents
news.alphastreet.comAUG 72 min read$ANIP

ANI Pharmaceuticals Releases Q2 2026 Financial Results

ANI Pharmaceuticals reported Q2 2026 results. Adjusted diluted EPS was $2.21, above the $2.09 estimate, and revenue rose to $266.0M from $211.4M a year earlier. Adjusted net income was $47.6M. Cortrophin Gel revenue was $117.1M, up 43.5%. Full-year adjusted EPS guidance is $9.19 to $9.69.

Original reporting
news.alphastreet.com
Published Aug 7, 2026, 7:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ANI Pharmaceuticals Releases Q2 2026 Financial Results — source image
Source · news.alphastreet.com
Decision brief

The 30-second read

$ANIPBullishMed
01

Why it matters

Q2 results and FY2026 adjusted EPS guidance are the primary actionable items, informing earnings revision risk and near-term positioning.

02

Market read

A straightforward earnings and guidance update with a beat and a specific full-year EPS range, typically driving analyst estimate changes and trading flows.

03

What to watch

No details are provided on cash flow, gross margin, R&D spend, competitive dynamics, or any risks to the pipeline that could affect how guidance is valued.

Relevance 8/10Novelty 7/10Timing: post-market earnings release dated 2026-08-07

Background

ANI Pharmaceuticals is a biopharmaceutical company selling branded and generic products, with Cortrophin Gel highlighted as a key growth driver.

Company-level read

Ticker impact

$ANIPBullishMedium confidence
Context

ANI Pharmaceuticals reported Q2 2026 adjusted EPS of $2.21, beating $2.09, and set FY2026 adjusted EPS guidance of $9.19 to $9.69.

Expected impact

Likely positive reaction versus peers if guidance is viewed as credible and Cortrophin Gel growth sustains.

Evidence & confidence

The article provides concrete EPS, revenue growth, and full-year guidance, which are direct drivers for earnings revisions and sentiment.

Market effects

Sector

Reinforces demand and execution strength in specialty biopharma, potentially supporting sentiment toward similar branded/generic hybrids.

Regional

No specific regional demand or regulatory change cited.

Global

International revenue growth is mentioned, but no country-specific catalysts are provided.

Counterpoint

What could challenge this read

The beat may be partially offset by margin or product-mix concerns not discussed here, so the stock reaction could fade if investors scrutinize sustainability of Cortrophin Gel growth.

Key entities

  • company
    ANI Pharmaceuticals, Inc.

    Reported Q2 2026 adjusted EPS of $2.21, revenue of $266.0M, and FY2026 adjusted EPS guidance of $9.19 to $9.69.

  • product
    Cortrophin Gel

    Flagship product with Q2 revenue of $117.1M, up 43.5% year over year.

Read at source← All news

Also covered by

3 outlets

Related articles

AUG 7
$ANIPMed

ANI Pharmaceuticals revenue rises 25.9% to $266M

ANI Pharmaceuticals reported record Q2 2026 net revenue of $266.0 million, up 25.9% year over year. GAAP net income was $24.7 million and adjusted EBITDA rose 32.4% to $71.6 million. Cortrophin Gel revenue grew 43.5% to $117.1 million, but full-year Cortrophin guidance was cut to $520–$540 million. ANIP shares fell 5.53% to $78.06.

grafa.com3 min
AUG 7
$ANIPMed

ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue

ANI Pharmaceuticals’ Q2 2026 earnings call covered Cortrophin Gel gout expansion and guidance. CEO Nikhil Alwani said sales force reps expanded to 180 by end-June, with over 95% generating multiple patient cases. Full-year Cortrophin guidance was trimmed to $520-$540 million, citing first-half performance and factors beyond case counts. Operating leverage investment is expected to drive improved margins in 2027.

finance.yahoo.com4 min
AUG 7
$ANIPMed

ANI PHARMACEUTICALS INC (ANIP): Results of Operations and Financial Condition

ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 anip-20260807xexx991.htm EX-99.1 Document Exhibit 99.1 ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results • Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year • Purified Cortrophin ® Gel net revenues of $117.1 million, an

SEC EDGAR 8-K6 min
AUG 7
$ANIPMedAI 8/10

ANI Pharmaceuticals Reports Second-Quarter 2026 Results, Raises Cortrophin Gel Guidance and Reaffirms Full-Year Outlook

ANI Pharmaceuticals (Nasdaq: ANIP) reported Q2 2026 net revenues of $266.0 million, up 25.9% year over year. Cortrophin Gel net revenues rose to $117.1 million (+43.5%). GAAP net income available to common shareholders was $24.7 million, and adjusted non-GAAP diluted EPS was $2.21. The company raised Cortrophin Gel guidance to $520-$540 million and reaffirmed full-year 2026 net revenue $1,080-$1,140 million and adjusted EBITDA $285-$300 million.

quiverquant.com6 min